Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hill

Showing results (51-60 of 595) with videos related to

Pageof 60
Sort By:
AIDS (London, England)|March 22, 2008
The Monark trial: where now for boosted protease inhibitor monotherapy?Andrew Hill, Bernard Hirschel, Christine Katlama
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 16, 2017
Development and refinement of the WAItE: a new obesity-specific quality of life measure for adolescentsYemi Oluboyede, Claire Hulme, Andrew Hill
HIV Clinical Trials|October 25, 2007
Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trialsAndrew Hill, Lindsay Hemmett, Bernard Wilson
HIV Clinical Trials|February 11, 2009
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patientsMarta Boffito, Diego Miralles, Andrew Hill
Applied Health Economics and Health Policy|June 21, 2011
Cost-efficacy analysis of the MONET trial using UK antiretroviral drug pricesBrian Gazzard, Andrew Hill, Anne Anceau
Journal of the International AIDS Society|November 14, 2014
Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break pointsAlice Raymond, Andrew Hill, Anton Pozniak
AIDS (London, England)|December 1, 2021
Is tenofovir disoproxil fumarate associated with weight loss?Shahini Shah, Victoria Pilkington, Andrew Hill
Open Forum Infectious Diseases|January 24, 2022
Ivermectin for COVID-19: Addressing Potential Bias and Medical FraudAndrew Hill, Manya Mirchandani, Victoria Pilkington
HIV Clinical Trials|June 21, 2014
Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trialsWilliam Powderly, Andrew Hill, Christiane Moecklinghoff
BMJ (Clinical Research Ed.)|October 10, 2012
Non-small cell lung cancerAndrew Hill, Patricia Fisher, Dan Yeomanson
Pageof 60

Showing results (51-60 of 595) with videos related to

Sort By:
Pageof 60
AIDS (London, England)|March 22, 2008
The Monark trial: where now for boosted protease inhibitor monotherapy?Andrew Hill, Bernard Hirschel, Christine Katlama
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 16, 2017
Development and refinement of the WAItE: a new obesity-specific quality of life measure for adolescentsYemi Oluboyede, Claire Hulme, Andrew Hill
HIV Clinical Trials|October 25, 2007
Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trialsAndrew Hill, Lindsay Hemmett, Bernard Wilson
HIV Clinical Trials|February 11, 2009
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patientsMarta Boffito, Diego Miralles, Andrew Hill
Applied Health Economics and Health Policy|June 21, 2011
Cost-efficacy analysis of the MONET trial using UK antiretroviral drug pricesBrian Gazzard, Andrew Hill, Anne Anceau
Journal of the International AIDS Society|November 14, 2014
Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break pointsAlice Raymond, Andrew Hill, Anton Pozniak
AIDS (London, England)|December 1, 2021
Is tenofovir disoproxil fumarate associated with weight loss?Shahini Shah, Victoria Pilkington, Andrew Hill
Open Forum Infectious Diseases|January 24, 2022
Ivermectin for COVID-19: Addressing Potential Bias and Medical FraudAndrew Hill, Manya Mirchandani, Victoria Pilkington
HIV Clinical Trials|June 21, 2014
Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trialsWilliam Powderly, Andrew Hill, Christiane Moecklinghoff
BMJ (Clinical Research Ed.)|October 10, 2012
Non-small cell lung cancerAndrew Hill, Patricia Fisher, Dan Yeomanson
Pageof 60